Prosthetic Heart Valve Market Forecast 2025-2035: Market to Reach USD 24.28 Billion by 2035 at 8.6% CAGR

The global prosthetic heart valve market is projected to reach a valuation of USD 10.60 billion in 2025 and is poised for significant expansion, climbing to USD 24.28 billion by the end of 2035. This robust growth, occurring at a compound annual growth rate (CAGR) of 8.6%, is driven by the rising prevalence of valvular heart diseases and the increasing adoption of minimally invasive cardiac procedures globally.

Request for Sample Report | Customize Report | Purchase Full Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=12537

Market snapshot: global Prosthetic Heart Valve Market demand 2026 - 2036

Market Size (2025): USD 10.60 Billion
Market Size (2035): USD 24.28 Billion
Anticipated CAGR (2025-2035): 8.6%
Leading Product Segment: Transcatheter Heart Valves (THV), holding a dominant 52.3% market share.
Secondary Product Segment: Tissue Heart Valves (Biological), accounting for 31.4% of the market.
Leading End Use: Hospitals, capturing a significant 71.5% market share.
Key Growth Regions: North America, East Asia, and Europe.
Top Companies: Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, CryoLife, Inc., Braile Biomédica, Colibri Heart Valve, LLC, JenaValve Technology, Inc., and Micro Interventional Devices, Inc.

Market Momentum (YoY Path)

The prosthetic heart valve market is characterized by consistent year-over-year value appreciation. Starting at USD 10.9 billion in 2026, the market is expected to grow to USD 13.5 billion by 2028 and reach USD 16.7 billion by 2030. By 2031, the valuation is projected at USD 18.6 billion, followed by a surge to USD 23.1 billion in 2033. Ultimately, the market is forecasted to hit USD 28.6 billion by 2035 and culminate in a USD 31.8 billion valuation by 2036.

Why the Market is Growing

Market expansion is primarily fueled by the aging global population, which is more susceptible to degenerative heart valve conditions. Furthermore, the shift from traditional open-heart surgeries toward minimally invasive transcatheter therapies has significantly improved patient outcomes and reduced recovery times. Technological advancements in valve durability and the development of next-generation transcatheter aortic valve replacement (TAVR) systems are also major catalysts for growth.

Segment Spotlight

1) Product Type

Transcatheter Heart Valves (THV) represent the largest segment, commanding 52.3% of the market. Their popularity stems from the ability to replace damaged valves via catheter-based delivery, eliminating the need for sternotomies. Tissue Heart Valves (Biological) follow with a 31.4% share, favored for their low risk of blood clots compared to mechanical alternatives.

2) End Use

Hospitals remain the primary setting for valve replacement procedures, holding 71.5% of the market. This dominance is attributed to the presence of specialized cardiac surgical teams, advanced imaging infrastructure, and high-volume patient throughput.

3) Regional Performance

North America leads the global landscape, while East Asia is emerging as a high-growth corridor due to improving healthcare infrastructure and an increasing patient pool in countries like China and India.

Drivers, Opportunities, Trends, Challenges

Drivers: The primary driver is the increasing incidence of aortic stenosis and mitral regurgitation. As diagnostic capabilities improve, more patients are being identified as candidates for valve replacement therapy.

Opportunities: There is a significant opportunity in the development of "dry" tissue valves and polymer-based valves that do not require specialized storage or anticoagulation therapy, potentially reaching underserved markets with limited specialized care.

Trends: A major trend is the move toward sutureless and rapid-deployment valves, which reduce cross-clamp times during surgery. Additionally, the expansion of TAVR indications to include low-risk patient populations is reshaping treatment protocols.

Challenges: High procedure costs and the complexity of regulatory approvals for new biological materials remain the primary hurdles. Furthermore, limited access to advanced cardiac care in emerging economies restricts total market penetration.

Country Growth Outlook (CAGR)

The market is projected to witness diverse growth rates across key regions between 2026 and 2036, with India leading the expansion at a CAGR of 13.5%, followed closely by China at 12.8%. In North America, the USA is expected to grow at a CAGR of 11.1%, while Brazil in South America follows with 10.9%. European markets also show steady progress, with Germany projected at 10.2%, France at 9.8%, and the UK at 9.5%.

Competitive Landscape

The market is highly consolidated, with a few major players leading innovation. Key companies such as Edwards Lifesciences, Medtronic, and Abbott Laboratories dominate through extensive R&D and strategic acquisitions. Smaller players like JenaValve and Colibri Heart Valve focus on niche transcatheter technologies to gain market foothold.

Read More: https://www.factmr.com/report/prosthetic-heart-valve-market

To View Related Report:

Automated Blood Tube Labeler & Specimen Transport Box Market https://www.factmr.com/report/automated-blood-tube-labeler-and-specimen-transport-box-market
Surgical Kits Market https://www.factmr.com/report/surgical-kits-market
Gel Documentation Systems Market https://www.factmr.com/report/gel-documentation-systems-market
Knee Cartilage Repair Market https://www.factmr.com/report/knee-cartilage-repair-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.